Alpine Immune Sciences, Inc.

Report azionario NasdaqGM:ALPN

Capitalizzazione di mercato: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Alpine Immune Sciences Gestione

Criteri Gestione verificati 3/4

Alpine Immune Sciences Il CEO è Mitch Gold, nominato in Jun2016, e ha un mandato di 7.92 anni. la retribuzione annua totale è $ 2.92M, composta da 20.5% di stipendio e 79.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.019% delle azioni della società, per un valore di $ 860.60K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 6.1 anni.

Informazioni chiave

Mitch Gold

Amministratore delegato

US$2.9m

Compenso totale

Percentuale dello stipendio del CEO20.51%
Mandato del CEO7.9yrs
Proprietà del CEO0.02%
Durata media del management4.3yrs
Durata media del Consiglio di amministrazione6.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Apr 11

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Summary Vertex Pharmaceuticals Incorporated is acquiring Alpine Immune Sciences, Inc. for $4.9 billion in cash to obtain the use of povetacicept for IgAN and other kidney disorders. Positive results of povetacicept for treatment of patients with IgAN were first revealed at ASN Kidney Week In November 2023, with additional positive data just released the other day. Povetacicept is also being explored in RUBY-4 study targeting patients with autoimmune cytopenias; Data from this study will be released at a medical meeting in the 1st half of 2024. A phase 2 trial initiation, using povetacicept for the treatment of patients with systemic lupus erythematosus, is expected in the 2nd half of 2024. Read the full article on Seeking Alpha
Articolo di analisi • Mar 21

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) investors will be delighted, with the company turning in some strong...
Articolo di analisi • Mar 20

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Alpine...
Seeking Alpha • Mar 07

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Summary Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate. Povetacicept has shown promising results in a Phase 2 study for the treatment of IgA nephropathy, with significant reductions in proteinuria and disease-related biomarkers. The market potential for povetacicept in the IgA nephropathy indication alone is estimated to be worth billions of dollars, making it a potentially lucrative asset for Alpine. There's plenty of competition in the IgAN space, however, including two recently approved drugs and two pipeline assets with the same MoA as povetacicept. These assets belong to Vera Therapeutics and Novartis, and it's difficult to pick a winning candidate, albeit Alpine's is the least advanced. As such, I'm not sure the company fully justifies its $2.5bn market cap - I'm on the sidelines until more data is shared. Read the full article on Seeking Alpha
Articolo di analisi • Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Articolo di analisi • Dec 19

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Despite an already strong run, Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shares have been powering on, with a gain...
Articolo di analisi • Sep 23

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 11

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

With a median price-to-sales (or "P/S") ratio of close to 11.6x in the Biotechs industry in the United States, you...
Articolo di analisi • Dec 12

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Sep 20

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences (NASDAQ:ALPN) stock dropped 13% after the bell on Tuesday after the firm announced an underwritten public offering of $100M of shares and pre-funded warrants to buy stock. Underwriters will be granted an option for 30 days to buy up to an additional $15M of shares at the offering price. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms.
Articolo di analisi • Aug 09

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Apr 25

Alpine: Rest Before Rallying Again

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships. Despite not having much further catalyst this year, the company is set to release data of a Phase 1 trial studying ALPN303 by mid-year.
Articolo di analisi • Apr 12

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Articolo di analisi • Sep 18

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Articolo di analisi • Aug 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Celebrations may be in order for Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders, with the analysts...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mitch Gold rispetto agli utili di Alpine Immune Sciences?
DataCompenso totaleStipendioUtili della società
Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$3mUS$599k

-US$32m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$64m

Dec 31 2022US$3mUS$544k

-US$58m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$47m

Dec 31 2021US$3mUS$523k

-US$50m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$500k

-US$28m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$33m

Mar 31 2020n/an/a

-US$35m

Dec 31 2019US$2mUS$485k

-US$42m

Sep 30 2019n/an/a

-US$47m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$400k

-US$36m

Sep 30 2018n/an/a

-US$30m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$11m

Dec 31 2017US$2mUS$300k

-US$8m

Compensazione vs Mercato: La retribuzione totale di Mitch ($USD 2.92M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.03M ).

Compensazione vs guadagni: La retribuzione di Mitch è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Mitch Gold (55 yo)

7.9yrs
Mandato
US$2,921,224
Compensazione

Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Mitchell Gold
Executive Chairman & CEO7.9yrsUS$2.92m0.019%
$ 860.6k
Stanford Peng
President and Head of Research & Development5.1yrsUS$1.75m0.43%
$ 19.2m
Paul Rickey
Senior VP7.1yrsUS$1.28mNessun dato
Ulrich Fuhs
VP of Finance & Chief Accounting Officerless than a yearNessun dato0.044%
$ 2.0m
M. Yi
Chief Technology Officerless than a yearNessun datoNessun dato
Michelle Greenblatt
Director of Investor Relations & Corporate Communicationsno dataNessun datoNessun dato
Remy Durand
Chief Business Officer4.3yrsNessun dato0.15%
$ 6.6m
Andrew Sandler
Chief Medical Officer1.8yrsNessun datoNessun dato
4.3yrs
Durata media
52yo
Età media

Gestione esperta: Il team dirigenziale di ALPN è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Mitchell Gold
Executive Chairman & CEO9.3yrsUS$2.92m0.019%
$ 860.6k
Robert Conway
Independent Director6.8yrsUS$110.21k0.073%
$ 3.2m
James Topper
Independent Director7.9yrsUS$101.46k0%
$ 0
Peter Thompson
Independent Director7.9yrsUS$103.96k0%
$ 0
Rafi Ahmed
Member of Scientific Advisory Board5.5yrsNessun datoNessun dato
Xiangmin Cui
Independent Director5.3yrsUS$100.21k0%
$ 0
Andrew Scharenberg
Scientific Advisory Board Chairmanno dataNessun datoNessun dato
Christopher Peetz
Independent Director6.1yrsUS$98.96k0.0028%
$ 123.5k
John Thompson
Member of Scientific Advisory Board5.5yrsNessun datoNessun dato
Manish Butte
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Paul Tumeh
Member of Scientific Advisory Boardno dataNessun datoNessun dato
James Welsh
Member of Scientific Advisory Board5.5yrsNessun datoNessun dato
6.1yrs
Durata media
58yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALPN sono considerati esperti (durata media dell'incarico 6.1 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/05/21 02:33
Prezzo dell'azione a fine giornata2024/05/17 00:00
Utili2024/03/31
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Alpine Immune Sciences, Inc. è coperta da 14 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Gao Yi ChenBerenberg
Vamil DivanGuggenheim Securities, LLC
Joseph PantginisH.C. Wainwright & Co.